PRESS RELEASE published on 05/02/2024 at 12:30, 4 months 26 days ago Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024 Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula
BRIEF published on 04/25/2024 at 13:05, 5 months 3 days ago Moderna to Present Diverse Research Studies at ESCMID Global Congress COVID-19 Vaccine Moderna Vaccine Research Influenza Vaccine ESCMID Congress
PRESS RELEASE published on 04/25/2024 at 13:00, 5 months 3 days ago Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress Moderna, Inc. to present data on COVID-19, influenza, respiratory syncytial virus, and cytomegalovirus vaccines at ESCMID Global Congress in Barcelona, Spain COVID-19 Moderna Inc. Barcelona Vaccines ESCMID Global Congress
BRIEF published on 04/24/2024 at 14:05, 5 months 4 days ago Moderna Collaborates with OpenAI to Enhance mRNA Medicines Using Advanced AI Healthcare Innovation MRNA Technology Moderna OpenAI AI Collaboration
PRESS RELEASE published on 04/24/2024 at 14:00, 5 months 4 days ago Moderna and OpenAI Collaborate To Advance mRNA Medicine Moderna and OpenAI collaborate to integrate generative AI tools, like ChatGPT Enterprise, into operations to enhance AI culture and augment employee roles for maximum impact on patients Generative AI Machine Learning Moderna OpenAI ChatGPT Enterprise
BRIEF published on 04/17/2024 at 13:05, 5 months 11 days ago Moderna to Present Q1 2024 Financial Results in May Financial Results Conference Call Webcast Moderna Q1 2024
PRESS RELEASE published on 04/17/2024 at 13:00, 5 months 11 days ago Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 Moderna, Inc. will host a live conference call to report Q1 2024 financial results and provide a corporate update. Moderna is a leader in mRNA medicine revolutionizing disease treatment Financial Results Conference Call Corporate Update Moderna Inc. MRNA Medicine
BRIEF published on 04/03/2024 at 17:05, 5 months 25 days ago Moderna's mRNA Therapy for Propionic Acidemia Shows Promise in Early-Stage Trial Gene Therapy Clinical Trial Moderna MRNA Therapy Propionic Acidemia
PRESS RELEASE published on 04/03/2024 at 17:00, 5 months 25 days ago Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature Moderna, Inc. announced interim data for mRNA-3927 therapy for propionic acidemia published in Nature, showing signs of clinical benefit and safety. Ongoing global trial evaluates safety and efficacy in participants with PA Clinical Trial Moderna Propionic Acidemia MRNA-3927 Genetic Disorder
BRIEF published on 03/27/2024 at 11:35, 6 months 1 day ago Moderna Announces Significant Advancements in Vaccine Development Programs COVID-19 MRNA Technology Moderna Vaccine Development Phase 3 Clinical Trials
Published on 09/28/2024 at 02:06, 21 hours 32 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 21 hours 38 minutes ago Quantum Biopharma Provides Corporate Update
Published on 09/28/2024 at 02:00, 21 hours 38 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 23 hours 28 minutes ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 9 hours 36 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 1 hour ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 1 hour ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 4 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 4 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 5 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 5 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 5 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 5 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024